The chief executive, Chris Roberts, said patient and doctor response to the
Nucleus 5 device was overwhelmingly positive and the new technology would form
the bulk of the company's total unit sales over the next six months. Unveiling
the company's first-half earnings yesterday, Dr Roberts did